WeightCare review

WeightCare offers more than a prescription transaction: its public model includes a physician consultation, ongoing messaging, medication delivery and support from coaches or member-success staff. Its simplest published comparison is $399 monthly for compounded semaglutide and $499 monthly for tirzepatide. Lower headlines depend on longer plans, introductory supply, dose limits or a particular payment arrangement. The tirzepatide starter and renewal amounts differ, and some program pages repeat inconsistent state exclusions. The service is a plausible choice for someone who wants more structured support and can commit to a clearly specified plan, but it is important to compare the full payment and continuation dose rather than the first advertised monthly equivalent. The strict refund policy after submission of the medical questionnaire is another reason to resolve the plan details before enrolling.

WeightCare’s Terms of Service identify Weightless Medical LLC. The site markets physician-supervised weight management with a wider wellness catalog, including NAD+, sermorelin, B12 and separate low-dose programs. It describes board-certified physicians, health coaching and ongoing support, but the reviewed product and policy pages do not establish a named dispensing pharmacy or a single named clinical group for every order. That leaves practical questions about who will prescribe, who will dispense, and which organization handles a problem with the medicine. The homepage offers telephone, email and chat support and gives published business hours, which are useful contact options without constituting a guarantee of immediate clinician access. Its weight-care programs are presented as self-pay, with potential HSA/FSA use depending on the patient’s plan. The wider wellness products should be considered separately from the primary weight-management service.

The patient begins an intake and provides medical history before a telehealth consultation. WeightCare says the assigned physician reviews eligibility, chooses a plan if appropriate and sends the prescription to a pharmacy for delivery. Continuing secure physician messaging, clinical check-ins and member-success support are advertised as part of care. The site describes cold-pack shipment and an approximate delivery window after prescribing, which remains subject to pharmacy processing and location. Dose changes need the physician’s approval rather than a consumer choosing a higher package independently. Program terms differ between a new-patient starter supply, a continuation plan and higher-dose treatment, so a patient transferring from another provider should explain the existing dose before purchasing. State restrictions also need a plan-specific check: recurring FAQ language excludes Alaska, Hawaii, Louisiana and Mississippi, while another semaglutide three-month passage additionally excludes Alabama. That conflict is a reason to confirm eligibility before submitting the questionnaire, not to assume the most permissive list applies.

Semaglutide is listed at $399 for a flexible monthly program. The public page gives $747 for three months, equivalent to $249 per month, and headline equivalents of $215 for six months and $139 for twelve months. The page describes longer options as payable at the start in some sections, while also offering financing, so verify the total due and any lender agreement rather than assuming the equivalent is an ordinary monthly subscription. For tirzepatide, the page lists $499 month to month, a three-month starter at $299 per month and a six-month plan at $275 per month, with the latter two generally limited to doses up to 7.5 mg weekly. Its renewal FAQ says a three-month continuation at that dose is $997, while higher-dose options through 15 mg are $1,350 for three months or $2,150 for six months. A twelve-month offer displays a $216 monthly equivalent with any dose language, creating another plan to confirm rather than blending all prices into one. A lower starter amount therefore does not mean the same price persists as treatment changes. The refund policy allows a full refund if the physician finds the patient ineligible or if the request comes before submission of the medical questionnaire. After submission, refunds are generally unavailable. Cancellation stops future charges and keeps access through the paid period, without automatic proration. An approved partial refund on a longer plan may value already supplied medication at its regular package price, reducing the amount returned.

WeightCare’s primary weight-loss products are compounded semaglutide and tirzepatide. The official disclaimer distinguishes them from branded Wegovy, Zepbound, Ozempic and Mounjaro and states that compounded drugs are not FDA-approved. References to branded medicines elsewhere on the site should not be understood as meaning the $399 or $499 package delivers a branded pen. Ask for the actual ingredient, additives if any, strength, quantity and pharmacy before comparing it with another offer. WeightCare also advertises semaglutide and tirzepatide microdosing programs alongside NAD+ and sermorelin. A microdose wellness program is not the same clinical proposition as a standard weight-management prescription; its dose, purpose and evidence need separate discussion. Neither a lower dose nor included coaching guarantees safety, a specific weight change or a longevity benefit. The clinician should explain why the prescribed formulation and schedule match the patient’s needs, how adverse effects are handled, and what would change or stop treatment.